Lv1
70 积分 2025-02-21 加入
[IgA nephropathy: new targeted therapies and prospects]
1个月前
已完结
The pathogenesis of IgA nephropathy and implications for treatment
1个月前
已完结
Enteric and Controlled-Release Budesonide in IgA Nephropathy: Expanding Access While Refining Evidence
1个月前
已完结
Steps forward in the treatment of IgA nephropathy
1个月前
已完结
Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis
1个月前
已完结
Review of IgA Nephropathy
1个月前
已完结
IgA Nephropathy in Adults
1个月前
已完结
Abstract No: 270 Efficacy and Predictive Factors of Targeted-Release Budesonide in Patients With IgA Nephropathy: A Retrospective Cohort Study
1个月前
已关闭
Abstract No: 044 Targeted-Release Budesonide in IgA Nephropathy: Real-World Effectiveness and Safety in a Chinese Cohort
1个月前
已关闭
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
1个月前
已完结
皖公网安备34019202002308
